Patient Safety Movement Foundation (PSMF) – a global non-profit dedicated to unifying those involved in the healthcare ecosystem, identifying challenges that are causing patient deaths, and creating actionable solutions to mitigate them – is pleased to announce the appointment of its new chairman of the board of directors – Michael A.E. Ramsay,"...

Hudson Valley Wireless (“HVW”) has selected and deployed Mavenir’s cloud-native LTE vEPC to support their recent project. HVW has formed official Public-Private Partnerships (P3) with local governments and works with State and Federal government to secure grant funding and deploy network in unserved and underserved communities.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200311005212/en/

We"...

Lebanon has a long history of economic and political instability. In the past, local insurers have been successful at navigating this challenging environment. However, recent civil unrest and a ballooning public debt have increased the level of economic uncertainty, which is negatively impacting the credit quality of Lebanon’s insurance market.

In a new Best’s Special Report, “Lebanese Insurance Market Faces Mounting Uncertainty”, AM Best notes that in contrast with the wider Middle East and North Africa region, the Lebanese insurance market overall"...

The LEGO Group announced a partnership with Nintendo that will change the way people interact with Super Mario in the physical world and engage in LEGO® experiences.

Both companies share a passion for innovation and play and their collaboration has led to a reimagination of the LEGO building experience, enabling an entirely new way to play inspired by the beloved video game icon, Super Mario.

Neither a video game nor a traditional LEGO brick-based set, LEGO® Super Mario™ is a new"...

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of empagliflozin to reduce the risk of kidney disease progression and cardiovascular death in adults with chronic kidney disease, Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced. The designation was granted for the clinical investigation of empagliflozin in adults with chronic kidney disease. This Fast Track designation for empagliflozin underscores the urgent need for new treatment options for people living with chronic kidney disease worldwide, many of whom are at risk of progressing to end-stage kidney disease.1